Back to results
US 12,215,145 B2Granted
Treatment of headache using anti-CGRP antibodies
AssigneeH. Lundbeck A/S
InventorsRoger K. Cady, Jeffrey T. L. Smith, Joseph Hirman, Barbara Schaeffler, Lahar Mehta
Life of this patent
Estimating the term…
Abstract
Methods for immediate relief of migraine or headache are provided comprising the administration of an anti-CGRP antagonist antibody to a patient in need thereof.
Claims28
A method of treating migraine in a patient in need thereof, the method comprising intravenously administering to the patient a humanized monoclonal antibody comprising:
- (A) a variable light chain polypeptide comprising light chain complementary determining region (CDR) 1, 2, and 3 polypeptide sequences of SEQ ID NO:
- 224, SEQ ID NO:
- 226, and SEQ ID NO:
- 228, respectively, and
- (B) a variable heavy chain polypeptide comprising heavy chain CDR 1, 2, and 3 polypeptide sequences of SEQ ID NO:
- 204, SEQ ID NO:
- 206, and SEQ ID NO:
- 208, respectively,
- wherein the humanized monoclonal antibody is administered to the patient at a dose of about 100 mg, the administration begins while the patient is experiencing a migraine attack, and the prevention of one or more symptoms is experienced by the patient within a short time period post-infusion with said antibody, such as within minutes or a few hours, such as within 10 minutes, 20 minutes, 30 minutes, 60 minutes, 1 hour, 2 hours or 6 hours.
6 more elements
A method of providing acute treatment of migraine in a patient in need thereof, the method comprising intravenously administering to the patient about 100 mg of a humanized monoclonal antibody comprising:
- (A) a variable light chain polypeptide comprising light chain complementary determining region (CDR) 1, 2, and 3 polypeptide sequences of SEQ ID NO:
- 224, SEQ ID NO:
- 226, and SEQ ID NO:
- 228, respectively, and
- (B) a variable heavy chain polypeptide comprising heavy chain CDR 1, 2, and 3 polypeptide sequences of SEQ ID NO:
- 204, SEQ ID NO:
- 206, and SEQ ID NO:
- 208, respectively,
- wherein the administration of the humanized monoclonal antibody begins while the patient is experiencing a migraine attack, and wherein said acute treatment of migraine comprises a reduction in headache pain within about four hours following the intravenous administration of the humanized monoclonal antibody.
6 more elements
Dependencies are inferred from the claim text.